JP2015522040A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522040A5
JP2015522040A5 JP2015520705A JP2015520705A JP2015522040A5 JP 2015522040 A5 JP2015522040 A5 JP 2015522040A5 JP 2015520705 A JP2015520705 A JP 2015520705A JP 2015520705 A JP2015520705 A JP 2015520705A JP 2015522040 A5 JP2015522040 A5 JP 2015522040A5
Authority
JP
Japan
Prior art keywords
composition
kit
lactalbumin
antibiotic
kit according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522040A (ja
JP6223444B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049437 external-priority patent/WO2014008465A2/en
Publication of JP2015522040A publication Critical patent/JP2015522040A/ja
Publication of JP2015522040A5 publication Critical patent/JP2015522040A5/ja
Application granted granted Critical
Publication of JP6223444B2 publication Critical patent/JP6223444B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520705A 2012-07-05 2013-07-05 蛋白質‐脂質複合体を用いた抗生物質治療の増強 Expired - Fee Related JP6223444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668390P 2012-07-05 2012-07-05
US61/668,390 2012-07-05
PCT/US2013/049437 WO2014008465A2 (en) 2012-07-05 2013-07-05 Potentiation of antibiotic treatment with a protein-lipid complex

Publications (3)

Publication Number Publication Date
JP2015522040A JP2015522040A (ja) 2015-08-03
JP2015522040A5 true JP2015522040A5 (https=) 2016-08-25
JP6223444B2 JP6223444B2 (ja) 2017-11-01

Family

ID=49882625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520705A Expired - Fee Related JP6223444B2 (ja) 2012-07-05 2013-07-05 蛋白質‐脂質複合体を用いた抗生物質治療の増強

Country Status (5)

Country Link
US (1) US9526766B2 (https=)
EP (1) EP2869831A4 (https=)
JP (1) JP6223444B2 (https=)
CA (1) CA2878292A1 (https=)
WO (1) WO2014008465A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
CN104068123B (zh) * 2014-06-26 2016-06-22 南京医科大学 一种乳白蛋白和油酸复合物抗肿瘤的保健饮料及其制备方法
WO2018070874A1 (en) * 2016-10-12 2018-04-19 Rijksuniversiteit Groningen Means and methods for reducing or avoiding antibiotic resistance and spread of virulence in human pathogens
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1032596T3 (da) 1997-11-21 2007-09-10 Nya Hamlet Pharma Ab Fremgangsmåde til fremstilling af lactalbumin
GB9725126D0 (en) 1997-11-27 1998-01-28 Svanborg Catharina Therapeutic agents
EP2094309A2 (en) * 2006-11-17 2009-09-02 Nya Hamlet Pharma AB Alpha-lactalbumin composition
EP2512460A4 (en) * 2009-12-18 2015-01-21 Exodos Life Sciences Ltd Partnership METHOD AND COMPOSITIONS FOR STABLE LIQUID ACTIVE FORMULATIONS

Similar Documents

Publication Publication Date Title
JP2015512386A5 (https=)
JP2015078220A5 (https=)
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
HRP20211086T1 (hr) Pomoćna farmaceutska sredstva s kontroliranim otpuštanjem i slojeviti kompleks za uključivanje ciklodekstrina
WO2016070151A8 (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
JP2013518107A5 (https=)
JP2013047268A5 (https=)
JP2012513467A5 (https=)
JP2022501330A5 (https=)
JP2016511753A5 (https=)
BR112015029838A2 (pt) anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
CL2018000745A1 (es) Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa.
JP2015522040A5 (https=)
JP2019513769A5 (https=)
JP2013532729A5 (https=)
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
CO6640318A2 (es) Formas de dosificación oral de bendamustina
JP2024009968A5 (https=)
JP2017513944A5 (https=)
RU2013154564A (ru) Способы и композиции для стимуляции роста безжировой массы тела
JP2017538675A5 (https=)
JP2017517574A5 (https=)
UA107155C2 (uk) Стабільна композиція для лікування герпесвірусних інфекцій
CO5750041A1 (es) Metodo para la fabricacion de un medicamento a base de una mezcla de acidos grasos poliinsaturados para la prevencion de infecciones respiratorias en infantes